Compare IXHL & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IXHL | PDSB |
|---|---|---|
| Founded | 2001 | 2005 |
| Country | Australia | United States |
| Employees | N/A | 10 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.0M | 42.4M |
| IPO Year | 2024 | 2015 |
| Metric | IXHL | PDSB |
|---|---|---|
| Price | $3.25 | $0.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.75 |
| AVG Volume (30 Days) | 75.0K | ★ 45.2M |
| Earning Date | 09-25-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.20 |
| 52 Week High | $6.39 | $1.55 |
| Indicator | IXHL | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 44.93 | 62.12 |
| Support Level | $3.10 | $0.58 |
| Resistance Level | $3.87 | $0.77 |
| Average True Range (ATR) | 0.20 | 0.12 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 14.08 | 65.07 |
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.